Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia (Q33611942)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

M I Wilde

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

K L Goa

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

1 April 1999

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

57

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

557-581

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Medical management of benign prostatic hyperplasia other than with hormones or alpha blockers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic Burden of Treated Benign Prostatic Hyperplasia in the United Kingdom

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential suppression of serum prostatic acid phosphatase and prostate-specific antigen by 5-alpha-reductase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Scandinavian Clinical Study of Finasteride in the Treatment of Benign Prostatic Hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, i

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the cost-effectiveness of various therapies for common prostatic disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An economic evaluation of finasteride for treatment of benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benign prostatic hyperplasia. Current pharmacological treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient satisfaction with finasteride in the treatment of symptomatic benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Flutamide and Finasteride on Rat Testicular Descent

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic issues and the management of benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urodynamic Effects of Finasteride in the Treatment of Bladder Outlet Obstruction due to Benign Prostatic Hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New words for old: lower urinary tract symptoms for "prostatism"

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The development of human benign prostatic hyperplasia with age

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of finasteride on adrenal steroidogenesis in men

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence for atrophy and apoptosis in the prostates of men given finasteride

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversible severe myopathy during treatment with finasteride

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged treatment with finasteride (a 5α‐reductase inhibitor) does not affect bone density and metabolism

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of finasteride on prostate specific antigen: review of available data

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential activities of androgen metabolizing enzymes in human prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen: critical issues for the practicing physician

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha 1-blockers vs 5 alpha-reductase inhibitors in benign prostatic hyperplasia. A comparative review

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proscar: five-year experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of finasteride on prostate-specific antigen density

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Finasteride, A Steroid 5α‐Reductase Inhibitor, Does Not Affect the Oxidative Metabolism of Antipyrine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5 alpha-reductase inhibitor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5 alpha-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gynecomastia and breast cancer during finasteride therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Finasteride: a slow-binding 5 alpha-reductase inhibitor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medical Treatment of Benign Prostatic Hyperplasia: 5α-Reductase Inhibitors and α-Adrenergic Antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urologists on a tightrope: coping with a changing economy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics and pharmacodynamics of finasteride

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10235693

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199957040-00008

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33611942&oldid=2195564888"